David A. Clump

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

Frank P. Vendetti, Pooja Karukonda, David A. Clump et al. · Journal of Clinical Investigation · 2018 · 209 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma

Masahiro Kikuchi, David A. Clump, Raghvendra M. Srivastava et al. · OncoImmunology · 2017 · 112 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

Gulidanna Shayan, Benjamin Kansy, Sandra P. Gibson et al. · Clinical Cancer Research · 2017 · 80 citations · Full text

Medicine, Immunology, Oncology +17

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial

Eric J. Sherman, Jonathan Harris, Keith C. Bible et al. · The Lancet Oncology · 2023 · 39 citations · Full text

Medicine, Oncology, Radiation Oncology +9

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

Frank P. Vendetti, Pinakin Pandya, David A. Clump et al. · JCI Insight · 2023 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17